LIGAND PHARMACEUTICALS INC (LGND)
Health Care · Specialty pharmaceuticals and biotech royalty aggregation · NASDAQ
A specialty pharma and royalty aggregator that monetizes a diverse portfolio of acquired drug assets, biotech stakes, and its proprietary solubilization technology platform.
What LIGAND PHARMACEUTICALS INC does
Ligand Pharmaceuticals is a biopharmaceutical company that develops and commercializes prescription medications and therapeutic products across multiple disease areas. The company operates through its own products, acquisitions of specialty pharmaceutical assets, and a portfolio approach involving investments in biotech companies and royalty streams. Ligand generates revenue from product sales, royalties from partnered assets, and sales of its proprietary drug formulation technology platform (Captisol).
Themes: ["Specialty pharmaceuticals"]
Fundamentals
- Price$322.61 as of 2026-07-09 close
- Market cap$6.4B as of 2026-07-10
- 1-year return+163.6% as of 2026-07-09 close
- P/E41.69 as of 2026-07-10
- Net margin+56.0% as of 2026-07-10
- Gross margin+95.3% as of 2026-07-10
- ROE+16.2% as of 2026-07-10
- Debt / equity0.45 as of 2026-07-10
- Revenue growth (YoY)+51.2% as of 2026-07-10
- Revenue CAGR (3y)+11.0% SEC XBRL
- Beta1.16 as of 2026-07-10
Dividend: 1-year non-decreasing per-share dividend streak (SEC XBRL).
Key risks (from latest filing)
["Dependence on royalty and milestone payments from partnered products and equity investments; changes in partner performance or asset valuations could materially impact revenue and financial results."]
Competitors & peers
- Takeda Pharmaceutical Company Limited
Fundamentals: Finnhub, as of 2026-07-10. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-09.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date.